AstraZeneca Drag Pulls FTSE 100 Down Despite Banking Gains

A 0.2% decline to 10,472.5 points marked a stagnant Thursday for the FTSE 100, as a sharp retreat from AstraZeneca overshadowed broader market optimism. While banking and mining sectors bolstered the index, the pharmaceutical giant’s late-stage trial results failed to meet expectations, effectively capping the session's upward momentum.

Editorial·July 9, 2026·reads: 289

AstraZeneca Drag Pulls FTSE 100 Down Despite Banking Gains

The pharmaceutical heavy hitter weighed heavily on the blue-chip index throughout the day, forcing a retreat that erased gains elsewhere. Investors had pinned hopes on the company’s recent performance, but the disappointing clinical data triggered a sell-off that the strength in financial and commodity stocks could not fully absorb.

Conversely, the midcap FTSE 250 showed resilience, climbing 1% to break a three-day losing streak. The divergence between the two indices underscores a market currently torn between sector-specific disappointments and a tentative recovery in domestic mid-sized firms.